No Data
No Data
We Think That There Are Issues Underlying Hangzhou TianMuShan Pharmaceutical EnterpriseLtd's (SHSE:600671) Earnings
Hangzhou Tianmushan Pharmaceutical Co., Ltd. 2024 Annual Report
Hangzhou Tianmushan Pharmaceutical Co., Ltd. 2024 Annual Report Summary
ST Eye Medicine (600671.SH) released its performance for the year 2024, with a net income of 15.2458 million yuan, turning a loss into profit.
ST Meiyao (600671.SH) released its annual report for 2024, with an annual revenue of 2...
Special Treat Eye Medicine (600671.SH): DeepSeek has not yet been applied to the company's Business.
On March 24, Gelonghui reported that ST Miao Pharmaceutical (600671.SH) stated on the interactive platform that the company adheres to the corporate vision of "Tianmu Mountain Pharmaceutical, making life better" and focuses on the research, development, production, and sales of pharmaceuticals, Active Pharmaceutical Ingredient, and health products, as well as Business such as pharmaceutical distribution and medical technical services. As of now, DeepSeek has not been applied to the company's Business. The company will continue to pay attention to AI technology research and applications.
Special Treat Eye Medicine (600671.SH): plans to increase capital by 50 million yuan to Huangshan Tianmu.
Gelonghui reported on March 10 that Special Treat's (600671.SH) announcement aims to accelerate the smooth construction of the capacity enhancement and technology transformation project of its wholly-owned subsidiary, Huangshan Timu, to facilitate the company's successful strategic transformation. The company plans to increase its investment in Huangshan Timu by 50 million RMB using its own funds. After the increase is completed, Huangshan Timu's registered capital will rise from 30 million RMB to 80 million RMB, and Huangshan Timu will remain a wholly-owned subsidiary of the company.